Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05855135

Assessment of Combined CCM and ICD Device in HFrEF

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%).

Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Individuals must meet all the following:

  • Patient is aged 18 years or older;
  • Patient meets the Stage C or D criteria of the Universal Definition of Heart Failure ;
  • Patient has HFrEF (LVEF ≤40%);
  • Patient is on GDMT for heart failure;
  • Patient has a Class I or Class II indication for an ICD
  • Patient has a reasonable expectation of meaningful survival of > 1 year;
  • Patient has either non-ischemic cardiomyopathy or ischemic cardiomyopathy and is at least 40 days post-MI, if an MI occurred;
  • Patient is willing to give informed consent, available for scheduled study follow-up visits, and able to complete all testing described in the study protocol at the investigational site location.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patients should not have severe AI or AS, and should not have MS; additionally, patients undergoing DE testing should not have severe MR;
  • Patients who have undergone mitral valve repair or clip within 90 days prior to study consent;
  • Cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;
  • Prior heart transplant or ventricular assist device;
  • Implanted mechanical tricuspid valve;
  • PR interval greater than 375ms or advanced AV block;
  • In situ S-ICD, pacemaker, or CRT device;
  • Indicated for CRT;
  • End stage renal disease, currently on dialysis, or with other major medical disorder (e.g. liver failure, terminal cancer);
  • Indicated for permanent bradyarrhythmia pacing;
  • Unstable angina pectoris within 30 days prior to study consent;
  • Pregnant or planning to become pregnant during the study;
  • Participating in another cardiac investigational device or drug study at the same time (or within 30 days prior to study consent); Note: Registries and other observational studies are acceptable.
  • Other criteria that preclude Optimizer INTEGRA CCM-D implantation and/or CCM therapy, as determined by Investigator.

Treatment and study plan

OPTIMIZER® Integra CCM-D System (Treatment Arm)

Device

The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.

Primary outcomes

  1. Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)

    Time frame: Implant

    Evaluate the device effectiveness in converting induced VF at the time of implantation.

  2. Device-related Complications (Primary Safety Objective)

    Time frame: Implant to 6 months

    Evaluate device-related complications through 6-months (excluding lead-related complications).

Secondary outcomes

  1. Inappropriate Shock Rate out to 6-months (Secondary Safety Objective)

    Time frame: Implant to 6 months

    Evaluate the incidence of inappropriate ICD shocks through the time when the last subject enrolled completes the 6-month visit.

Other outcomes

  1. Inappropriate Shock Rate out to 2-years

    Time frame: Implant to 2 years

    Evaluate the device effectiveness in converting spontaneous VT/VF through the time when the last subject enrolled completes the 6-month visit. Each subject will be followed for 2-years after implant to capture additional spontaneous episodes that may occur.

  2. Charging non-compliance

    Time frame: Implant to 2 years

    Evaluate subject charging non-compliance defined as >14 days between interval charging sessions, overall and frequency of non-compliance in the same subject.

  3. Longitudinal levels of activity

    Time frame: Implant to 2 years

    Track longitudinal levels of activity weekly via OPTIhome (when available) and identification of trends.

  4. Battery degradation and longevity

    Time frame: Implant to 2 years

    Assess battery degradation and longevity either remotely or during an in-person follow-up at 2 years (+/- 60 days) by recording QHR battery voltage as measured by the Integra CCM-D IPG. The measurement under nominal conditions is expected to be 2.85V or higher, consistent with a 20-year device longevity.

  5. Compare worsening heart failure events pre- and post-implant

    Time frame: 12 months prior to implant and 12 months post-implant

    Track unscheduled cardiovascular-related healthcare encounters from 12 months prior to implant, if available, to 12 months post-implant

  6. All-cause mortality

    Time frame: 1 and 2 years post-implant

    Assess all-cause mortality using Seattle Heart Failure Model (SHFM) and comorbidity burden as a predictive comparator at 1 year and 2 years post-implant

  7. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: Baseline to 6-months

    Compare change in subject's perception of their heart failure symptoms, as measured by KCCQ, from baseline to 6 months.

  8. EQ-5D-5L

    Time frame: Baseline to 6-months

    Compare change in subject's perception of their health status, as measured by the EQ-5D-5L, from baseline to 6 months.

  9. Six Minute Walk Distance (6MWD)

    Time frame: Baseline to 6 months

    Compare change in functional capacity, as measured by 6MWD, from baseline to 6 months.

Sponsors and collaborators

Lead sponsor

Impulse Dynamics

Industry

Registry information

Official study title

Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects With Heart Failure and Reduced Ejection Fraction

Acronym: INTEGRA-D

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
May 11, 2023
Registry last updated
May 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.